Clinical trials: Neurotrophic Keratitis, active
Dry Eye, Neurotrophic Keratitis
DOMPE -MT Neurotrophic Keratitis
TITLE: Toyos Clinic / A Phase 4 Study to Assess Longer Duration of Treatment with Cenegermin in Moderate to Severe Dry Eye-Associated Neurotrophic Keratitis
- Trial name
- NCT06947850
- Testing
- Cenegermin Ophthalmic Solution [Oxervate]
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Toyos Clinic
Autoimmune Diseases, Dry Eye
Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
Single-site, open label pilot study of 20 autoimmune patients diagnosed with dry eye demonstrating via the proparacaine challenge some peripheral corneal pain component.
- Conditions
- Autoimmune Diseases, Dry Eye, Neurotrophic Keratitis
- Trial name
- MNK (NCT06964269)
- Testing
- Acthar Gel 80 UNT/ML Injectable Solution
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Toyos Clinic
Neurotrophic Keratitis
A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis
This is a Phase II, double-blind, placebo-controlled study to evaluate the safety and efficacy of STSP-0902 ophthalmic solution in patients with neurotrophic keratitis (NK).
- Trial name
- NCT06975748
- Testing
- STSP-0902 ophthalmic solution
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Neurotrophic Keratitis
A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis
Objective: To evaluate the safety of Lacripep 4 μM Ophthalmic Solution and its effect on the ocular surface, visual function, corneal sensitivity, and quality of life of subjects with Stage 1 NK.
- Trial name
- NCT07568730
- Testing
- Lacripep, Vehicle Ophthalmic Solution
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- TearSolutions, Inc.
Persistent Corneal Epithelial Defect
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
This is a phase 3, randomized, multicenter, double-masked, parallel group, vehicle-controlled prospective clinical trial to evaluate the safety and efficacy of cenegermin in inducing complete epithelial healing in participants…
- Trial name
- NCT07519902
- Testing
- Cenegermin, Vehicle
- Where
- 77 sites in United States, Argentina and 12 more
- Volunteers
- 150 people
- Sponsor
- Dompé Farmaceutici S.p.A
Neurotrophic Keratopathy
A Phase 1/2, Single-Dose, Multicenter, Dose Escalation, Clinical Trial to Evaluate the Safety and Efficacy of MR-146: An Open-Label Part 1 in Participants With Stage 1 or 2 Neurotrophic Keratopathy and a Double-Masked Part 2 in Participants With Stage 2 Neurotrophic Keratopathy
The objective of this study is to evaluate the safety, tolerability, and biologically effective dose (BED) of MR-146 for the treatment of Stage 1 and Stage 2 Neurotrophic Keratopathy (NK)
- Trial name
- MR-146 (NCT07923045)
- Testing
- MR-146
- Where
- 11 sites in United States
- Volunteers
- 18 people
- Sponsor
- Viatris Inc.
Ocular Surface Disease, Neurotrophic Keratopathy Stage 1
Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency
STUDY OBJECTIVE To assess if acoltremon 0.003% improves tear production in patients with Stage 1 Neurotrophic Keratopathy.
- Trial name
- NCT07502378
- Testing
- Patients will receive topical Acoltremon 0.003% ophthalmic solution BID in both eyes over an 8 week period., Alternative would be patient exiting the trial and starting on tears or other standard of care.
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of South Florida
Neurotrophic Keratitis
A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis
The Sponsor is developing KB801, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human nerve growth factor (NGF) to the corneas of people…
- Trial name
- EMERALD-1 (NCT06999733)
- Testing
- KB801
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Krystal Biotech, Inc.
Neurotrophic Keratopathy, Exposure Keratopathy
Clinical Predictors of Visual Outcome in Patients Affected With Ocular Surface Diseases
This retrospective-prospective study aims to identify the diagnostic parameters most predictive of BSCVA in patients with OSD. Clinical, structural, and biochemical data will be collected from standard-of-care examinations and…
- Conditions
- Neurotrophic Keratopathy, Exposure Keratopathy, Limbal Stem Cell Deficiency (LSCD), Cornea Abnormality
- Trial name
- OSD (NCT07694817)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS San Raffaele
Persistent Corneal Epithelial Defect, Corneal Epithelial Disorders
Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatments for at least two weeks) will receive 8 weeks treatment of topical…
- Trial name
- NCT06919081
- Testing
- Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome, Vehicle Control
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Illinois Chicago
Ocular GVHD
The Prevalence of Hypoesthesia Related Keratitis in Ocular Graft Vs. Host Disease (GVHD) Patients
The Investigators hypothesize that the recalcitrant nature of ocular GVHD may be related to corneal nerve damage and corneal hypoesthesia.
- Trial name
- NCT04700657
- Testing
- corneal sensation test
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Indiana University
Neurotrophic Keratitis
Corneal Neurotization vs. Cenergermin for Neurotrophic Keratitis: A Pilot Study
This pilot study evaluates the feasibility and outcomes of two treatment approaches for corneal sensory dysfunction due to neurotrophic keratitis (NK): corneal neurotization surgery and topical Cenergermin (Oxervate).
- Trial name
- NCT07073729
- Testing
- Corneal Neurotization, Cenergermin
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Dry Eye
Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study
patients from a Neuro Ophthalmology who have dry eye, some of which have neurotrophic keratitis are being analyzed after treatment with Vevye
- Trial name
- NCT07566975
- Testing
- Cyclosporine ophthalmic solution 0.1%
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Neuro-Ophthalmology of Texas
Neurotrophic Keratopathy
Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy
Neurotrophic keratopathy (NK) is a condition where the cornea loses its capacity to feel pain and touch. This causes a decrease in the production of certain substances that maintain the integrity of the corneal epithelium (the…
- Trial name
- NCT04604834
- Testing
- PFAT first, APRP first
- Where
- Mexico
- Volunteers
- 39 people
- Sponsor
- Universidad Autonoma de Nuevo Leon